SYMPOSIUM ON SOLID TUMORSSmall Cell Lung Cancer
Section snippets
PATHOLOGY
Histologically, the tumor cells are small, round to ovoid or spindle shaped, with scant cytoplasm. The mitotic count is high; cells grow in clusters that exhibit neither glandular nor squamous organization. Electron microscopy shows dense-core neurosecretory granules 100 nm in diameter. Nearly all SCLC are immunoreactive for keratin, thyroid-transcription factor 1, and epithelial membrane antigen. Neuroendocrine and neural differentiation result in the expression of dopa decarboxylase,
ETIOLOGY AND PATHOGENESIS
The most important known cause of SCLC is cigarette smoking,9 accounting for approximately 95% of cases. Interaction of environmental factors with the genome of the respiratory epithelium results in carcinogenesis in susceptible patients.
Increasing evidence has implicated autocrine growth loops, proto-oncogenes, and tumor-suppressor genes in the pathogenesis of SCLC. Several chromosome and oncogene abnormalities have been identified in fresh SCLC tissues and cell lines, such as deletions on the
HEREDITARY PREDISPOSITION TO LUNG CANCER
The Genetic Epidemiology of Lung Cancer Consortium (GELCC) conducted the first family linkage study searching for susceptibility genes for lung cancer. This study identified linkage of lung, laryngeal, and pharyngeal cancer in families to a region on chromosome 6q23-25.32, 33, 34 Attempts at defining genetic susceptibility are ongoing. Studies have identified people with certain alleles of the CYP1A1 gene to have an increased capacity to metabolize procarcinogens derived from cigarette smoke
CLINICAL DIAGNOSIS AND STAGING
The most common presenting symptoms are dyspnea, persistent cough, and hemoptysis. Postobstructive pneumonia may be the presenting clinical syndrome. Small cell lung cancer is the most common malignant cause of superior vena cava syndrome. Metastatic disease can produce pain, headache, malaise, seizures, fatigue, anorexia, and weight loss. Common sites of metastasis include bone, liver, lymph node, the central nervous system, adrenal glands, subcutaneous tissue, and pleura.37 Pancoast tumor,
NATURAL HISTORY
Historical survival data for people with untreated SCLC came from an early VALCSG trial in which cyclophosphamide treatment was compared with placebo. In this trial, median survival was 12 weeks for patients with LD and 6 weeks for patients with ED. Small cell lung cancer is very responsive to chemotherapy, with major responses in 70% to 90% of cases on initial treatment. However, most patients relapse and die within 2 years. The most important prognostic features are disease stage, performance
Limited-Stage Disease
At diagnosis, approximately 30% of patients with SCLC have LD.48, 49, 50 Combined modality treatment with chemotherapy and concurrent radiotherapy is the current standard of treatment. Addition of radiation to chemotherapy produces modest but significant improvement in survival. Two meta-analyses have shown a 5% improvement in 3-year survival rates for patients receiving a combination of chemotherapy and radiation vs those receiving chemotherapy alone.51, 52
With its propensity for early
CONCLUSION
Small cell lung cancer remains a therapeutic challenge despite high initial responses to chemotherapy and radiotherapy. The 5-year survival is 15% to 25% for patients with LD-SCLC and less than 1% for patients with ED-SCLC. Concurrent chemoradiation therapy in patients with LD-SCLC and PCI are the primary advances made in therapy during the past decade. The fact that several promising molecularly targeted agents have not shown adequate activity in the clinical setting does not spell the doom of
REFERENCES (133)
- et al.
The Ras/Raf/MAPK Pathway
J Thorac Oncol
(2006) - et al.
A major lung cancer susceptibility locus maps to chromosome 6q23-25
Am J Hum Genet
(2004 Sep) - et al.
Paraneoplastic syndromes associated with lung cancer
Mayo Clin Proc
(1993) - et al.
Pancoast's syndrome and small cell lung cancer
Chest
(1982) - et al.
Hematological, biochemical and bone scan findings in patients with marrow carcinoma
Pathology
(1991) - et al.
Prognostic influence of TNM staging and the LDH levels in small cell carcinoma of the lung (SCCL)
Int J Radiat Oncol Biol Phys
(1986) - et al.
Small-cell lung cancer: state of the art
Clin Lung Cancer
(2002) - et al.
A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy
Chest
(1994) - et al.
Postchemotherapy resection of residual tumor in limited stage small cell lung cancer
Chest
(1987) - et al.
Surgical treatment for limited small-cell lung cancer: the University of Toronto Lung Oncology Group experience
J Thorac Cardiovasc Surg
(1991)
Is there ever a role for salvage operations in limited small-cell lung cancer?
J Thorac Cardiovasc Surg
Radiation dose escalation in limited-stage small-cell lung cancer
Int J Radiat Oncol Biol Phys
Importance of radiation dose in achieving improved loco-regional tumor control in limited-stage small-cell carcinoma: an update
Int J Radiat Oncol Biol Phys
Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer
Int J Radiation Oncol Biol Phys
Randomized comparison of etoposide-cisplatinum vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study
Ann Oncol
Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy
Eur J Cancer Clin Oncol
Prophylactic cranial irradiation in small cell lung cancer—an update
Lung Cancer
Cerebral toxicity in patients treated for small cell carcinoma of the lung
Mayo Clin Proc
Cancer Facts and Figures 2007
Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract 7082]
J Clin Oncol
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
J Clin Oncol
Changing patterns of lung cancer histology with age and gender
Thorax
Women at double risk of small cell lung cancer
BMJ
Rising incidence of SCLC in young women [letter]
Thorax
The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies
Am J Clin Pathol
Genetic etiology of lung cancer
Oncology (Williston Park)
Involvement of the RAF 1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer
Genes Chromosomes Cancer
Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts
Br J Cancer
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
Cancer Res
Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer
Anticancer Res
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer
Clin Cancer Res
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer
J Cell Mol Med
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
Br J Cancer
Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines
Cancer Res
In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor
Br J Cancer
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells
Proc Natl Acad Sci U S A
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
Oncogene
c-erbB2 expression in small-cell lung cancer is associated with poor prognosis
Int J Cancer
High prevalence of bcl-2 oncoprotein expression in small cell lung cancer
Anticancer Res
Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas
J Pathol
Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
Antisense Res Dev
Genetic analysis of chemoresistance in primary murine lymphomas
Nat Med
Molecular genetics of small cell lung carcinoma
Semin Oncol
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
Oncogene
Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
Cancer Res
Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression
Cancer Metastasis Rev
Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions
Cancer
Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Passive smoking, metabolic gene polymorphisms, and infant birth weight in a prospective cohort study of Chinese women
Am J Epidemiol
Cited by (396)
Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview
2024, Critical Reviews in Oncology/HematologyMild exposure to fine particulate matter promotes angiogenesis in non-small cell lung carcinoma
2023, Environmental PollutionEssential Surgical Plan Modifications After Virtual Reality Planning in 50 Consecutive Segmentectomies
2023, Annals of Thoracic SurgeryUpregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis
2024, Journal of Cellular and Molecular Medicine